Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
- PMID: 20346095
- PMCID: PMC2879558
- DOI: 10.1186/bcr2483
Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Abstract
There is a strong association between BRCA1 mutation carrier status and estrogen receptor-negative breast cancer. This has led to the idea that estrogen receptor-positive breast cancers in BRCA1 mutation carriers may be incidental or sporadic in nature and not as a direct result of BRCA1 dysfunction. A recent paper in Breast Cancer Research challenges this view.
Comment on
-
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.Breast Cancer Res. 2010;12(1):R12. doi: 10.1186/bcr2478. Epub 2010 Feb 11. Breast Cancer Res. 2010. PMID: 20149218 Free PMC article.
Similar articles
-
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.Clin Cancer Res. 2009 Mar 1;15(5):1514-8. doi: 10.1158/1078-0432.CCR-08-0640. Epub 2009 Feb 17. Clin Cancer Res. 2009. PMID: 19223511 Free PMC article. Review.
-
Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.Am J Surg Pathol. 2012 Oct;36(10):1483-8. doi: 10.1097/PAS.0b013e31825789ed. Am J Surg Pathol. 2012. PMID: 22613997
-
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.Clin Cancer Res. 2004 Mar 15;10(6):2029-34. doi: 10.1158/1078-0432.ccr-03-1061. Clin Cancer Res. 2004. PMID: 15041722
-
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.Clin Cancer Res. 2001 Jul;7(7):1937-45. Clin Cancer Res. 2001. PMID: 11448907
-
Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.Curr Opin Obstet Gynecol. 2008 Feb;20(1):68-73. doi: 10.1097/GCO.0b013e3282f42237. Curr Opin Obstet Gynecol. 2008. PMID: 18197009 Review.
Cited by
-
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013. PLoS One. 2013. PMID: 23704984 Free PMC article.
-
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22144499 Free PMC article.
References
-
- Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Kathryn A, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010;12:R12. doi: 10.1186/bcr2478. - DOI - PMC - PubMed
-
- Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G. Breast tumor immunophenotype of BRCA1 -mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001;7:1937–1945. - PubMed
-
- Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA. Estrogen receptor status in BRCA1 - and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029–2034. doi: 10.1158/1078-0432.CCR-03-1061. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous